Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 PsA risk framework

From: Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis

Disease-related risks (including functional concerns)
 • Assessment of symptoms (pain, stiffness, swelling, rash)
   Physical examination
   Joint examination
   PASI
 • Functional assessment
   Imaging (X-rays, MRI)
 • Quality of life (social interaction, sexual health, body image)
   SF-36 subscales
   EuroQoL-5 dimension
   PsAQoL
   Pain Disability Index
   PsAID
   Work ability
 • Documentation of extra-articular manifestations and/or comorbidities
 • Poor balance/risk of falls
   Fractures
Treatment-related risks
 • Contraindications
   NSAIDs in patients with IBD, CV disease
 • Adverse events
   Liver damage with methotrexate (obese patients particularly at risk)
 • Poor compliance/persistence
   Reduced efficacy of biologics
 • Routine laboratory monitoring with biologics
 • Immunogenicity with biologics
Psychosocial risks
 • Mental health (particularly depression, but also anxiety)
   SF-36 subscales
   PsAID
   DASS-21
 • Alcohol abuse
 • Self-esteem issues (especially in younger patients)
 • Social participation
   PsAID
  1. CV cardiovascular, DASS-21 Depression and Anxiety Stress Scale, IBD inflammatory bowel disease, MRI magnetic resonance imaging, NSAIDs nonsteroidal anti-inflammatory drugs, PASI Psoriasis Area and Severity Index, PsAID Psoriatic Arthritis Impact of Disease, PsAQoL Psoriatic Arthritis Quality of Life Questionnaire, SF-36 Short-form 36